Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In BioAge To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in BioAge between September 26, 2024 and January 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK  , Feb. 20, 2025 /PRNewswi ...

Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to its initial public offering [1][2]. Group 1: Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. - The company's lead product candidate, azelaprag, is designed to enhance weight loss as an orally available small-molecule agonist of the apelin receptor [3]. Group 2: Legal Allegations - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, concerning investors who purchased stock during BioAge's IPO on September 26, 2024 [2]. - The complaint alleges that BioAge misrepresented the safety and efficacy of its STRIDES Phase 2 trial for azelaprag, which was conducted in collaboration with Eli Lilly and Company [4]. Group 3: Trial and Stock Impact - BioAge's STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - Following the announcement of the trial's discontinuation on December 6, 2024, BioAge's stock price plummeted over 76%, from $20.09 to $4.65 per share within three days [6].

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=130521&from=4CLASS PERIOD: This lawsuit is on ...

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million. On December 19, 2024, BioArctic announced that Bio ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26 ...

STOCKHOLM, Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment.  Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally develop ...

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the azelaprag trial was unexpected, as the company had previously promoted the drug's potential [2]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [4]. - The firm aims to recover losses for investors caused by misleading statements or omissions that inflated stock prices [4].

LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA).IF YOU SUFFERED A LOSS ON YOUR BIOAGE INVESTMENTS, CLICK HERE BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between pursuant and/or traceable to the Registrat ...

RADNOR, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). T ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=127845&from=4CLASS PERIOD: This lawsuit is on ...